Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Account Payables (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Change in Account Payables data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 59.07% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $5.0 million, up 197.54%, while the annual FY2025 figure was $5.0 million, 197.54% up from the prior year.
  • Change in Account Payables reached $2.8 million in Q4 2025 per SNDX's latest filing, up from -$3.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $7.3 million in Q2 2025 and bottomed at -$6.7 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $653600.0, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Change in Account Payables: surged 266.77% in 2021, then tumbled 829.29% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $547000.0 in 2021, then crashed by 605.3% to -$2.8 million in 2022, then surged by 241.53% to $3.9 million in 2023, then soared by 71.98% to $6.7 million in 2024, then plummeted by 59.07% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $2.8 million in Q4 2025, -$3.5 million in Q3 2025, and $7.3 million in Q2 2025.